Your browser doesn't support javascript.
loading
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
Laparra, A; Kfoury, M; Champiat, S; Danlos, F X; Martin-Romano, P; Simonaggio, A; Baldini, C; Vuagnat, P; Mateus, C; Voisin, A L; Albiges, L; Besse, B; Even, C; Robert, C; Laghouati, S; Massard, C; Marabelle, A; Lambotte, O; Michot, J M.
Affiliation
  • Laparra A; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Kfoury M; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Champiat S; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Danlos FX; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Martin-Romano P; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Simonaggio A; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Baldini C; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Vuagnat P; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Mateus C; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Voisin AL; Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Albiges L; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Besse B; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France.
  • Even C; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Robert C; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France.
  • Laghouati S; Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Massard C; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France.
  • Marabelle A; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Lambotte O; Université Paris-Saclay, UMR 1184, Le Kremlin Bicêtre, France; Internal Medicine and Clinical Immunology Department, Assistance Publique-Hôpital de Paris, Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêt
  • Michot JM; Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: jean-marie.michot@gustaveroussy.fr.
Ann Oncol ; 32(7): 936-937, 2021 07.
Article in En | MEDLINE | ID: mdl-33865965
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Year: 2021 Document type: Article